Cargando…

Mitotic rate and S-phase fraction as prognostic factors in stage I cutaneous malignant melanoma.

Clinical data from 369 patients with clinical stage I cutaneous malignant melanoma treated in Kuopio University Hospital district between 1974 and 1989 with a mean follow-up of 6.4 years were analysed. Clinical parameters, histology, DNA index, S-phase fraction (SPF) and mitotic indices [mitotic act...

Descripción completa

Detalles Bibliográficos
Autores principales: Karjalainen, J. M., Eskelinen, M. J., Nordling, S., Lipponen, P. K., Alhava, E. M., Kosma, V. M.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1998
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150319/
https://www.ncbi.nlm.nih.gov/pubmed/9667668
_version_ 1782144598645145600
author Karjalainen, J. M.
Eskelinen, M. J.
Nordling, S.
Lipponen, P. K.
Alhava, E. M.
Kosma, V. M.
author_facet Karjalainen, J. M.
Eskelinen, M. J.
Nordling, S.
Lipponen, P. K.
Alhava, E. M.
Kosma, V. M.
author_sort Karjalainen, J. M.
collection PubMed
description Clinical data from 369 patients with clinical stage I cutaneous malignant melanoma treated in Kuopio University Hospital district between 1974 and 1989 with a mean follow-up of 6.4 years were analysed. Clinical parameters, histology, DNA index, S-phase fraction (SPF) and mitotic indices [mitotic activity index (MAI) and volume-corrected mitotic index (M/V index)] were correlated with the outcome of the disease to establish their value as predictors of stage I cutaneous malignant melanoma. In univariate survival analyses, bleeding, gender, tumour thickness, level of invasion according to Clark, TNM category, MAI, M/V index and SPF were the most significant predictors of recurrence-free (RFS) and overall survival. In Cox's multivariate analysis, tumour thickness (P = 0.0021), bleeding (P = 0.0106) and M/V index (P = 0.0058) predicted poor RFS in the 259 patients available for the analysis. Poor overall survival was predicted by MAI (P = 0.0002), bleeding (P = 0.004), SPF (P = 0.009) and male gender (P = 0.034). The present results indicate that mitotic activity index (MAI), volume-corrected mitotic index (M/V index) and S-phase fraction (SPF) are important prognostic factors in addition to the well-established Breslow thickness in stage I cutaneous malignant melanoma.
format Text
id pubmed-2150319
institution National Center for Biotechnology Information
language English
publishDate 1998
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-21503192009-09-10 Mitotic rate and S-phase fraction as prognostic factors in stage I cutaneous malignant melanoma. Karjalainen, J. M. Eskelinen, M. J. Nordling, S. Lipponen, P. K. Alhava, E. M. Kosma, V. M. Br J Cancer Research Article Clinical data from 369 patients with clinical stage I cutaneous malignant melanoma treated in Kuopio University Hospital district between 1974 and 1989 with a mean follow-up of 6.4 years were analysed. Clinical parameters, histology, DNA index, S-phase fraction (SPF) and mitotic indices [mitotic activity index (MAI) and volume-corrected mitotic index (M/V index)] were correlated with the outcome of the disease to establish their value as predictors of stage I cutaneous malignant melanoma. In univariate survival analyses, bleeding, gender, tumour thickness, level of invasion according to Clark, TNM category, MAI, M/V index and SPF were the most significant predictors of recurrence-free (RFS) and overall survival. In Cox's multivariate analysis, tumour thickness (P = 0.0021), bleeding (P = 0.0106) and M/V index (P = 0.0058) predicted poor RFS in the 259 patients available for the analysis. Poor overall survival was predicted by MAI (P = 0.0002), bleeding (P = 0.004), SPF (P = 0.009) and male gender (P = 0.034). The present results indicate that mitotic activity index (MAI), volume-corrected mitotic index (M/V index) and S-phase fraction (SPF) are important prognostic factors in addition to the well-established Breslow thickness in stage I cutaneous malignant melanoma. Nature Publishing Group 1998-06 /pmc/articles/PMC2150319/ /pubmed/9667668 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Karjalainen, J. M.
Eskelinen, M. J.
Nordling, S.
Lipponen, P. K.
Alhava, E. M.
Kosma, V. M.
Mitotic rate and S-phase fraction as prognostic factors in stage I cutaneous malignant melanoma.
title Mitotic rate and S-phase fraction as prognostic factors in stage I cutaneous malignant melanoma.
title_full Mitotic rate and S-phase fraction as prognostic factors in stage I cutaneous malignant melanoma.
title_fullStr Mitotic rate and S-phase fraction as prognostic factors in stage I cutaneous malignant melanoma.
title_full_unstemmed Mitotic rate and S-phase fraction as prognostic factors in stage I cutaneous malignant melanoma.
title_short Mitotic rate and S-phase fraction as prognostic factors in stage I cutaneous malignant melanoma.
title_sort mitotic rate and s-phase fraction as prognostic factors in stage i cutaneous malignant melanoma.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150319/
https://www.ncbi.nlm.nih.gov/pubmed/9667668
work_keys_str_mv AT karjalainenjm mitoticrateandsphasefractionasprognosticfactorsinstageicutaneousmalignantmelanoma
AT eskelinenmj mitoticrateandsphasefractionasprognosticfactorsinstageicutaneousmalignantmelanoma
AT nordlings mitoticrateandsphasefractionasprognosticfactorsinstageicutaneousmalignantmelanoma
AT lipponenpk mitoticrateandsphasefractionasprognosticfactorsinstageicutaneousmalignantmelanoma
AT alhavaem mitoticrateandsphasefractionasprognosticfactorsinstageicutaneousmalignantmelanoma
AT kosmavm mitoticrateandsphasefractionasprognosticfactorsinstageicutaneousmalignantmelanoma